- Home
- HAFN vs GH Comparison
HAFN vs GH Comparison
Compare HAFN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- GH
- Stock Information
- Founded
- HAFN 2012
- GH 2011
- Country
- HAFN Bermuda
- GH United States
- Employees
- HAFN N/A
- GH N/A
- Industry
- HAFN
- GH Medical Specialities
- Sector
- HAFN
- GH Health Care
- Exchange
- HAFN Nasdaq
- GH Nasdaq
- Market Cap
- HAFN 4.0B
- GH 3.0B
- IPO Year
- HAFN N/A
- GH 2018
- Fundamental
- Price
- HAFN $7.00
- GH $23.73
- Analyst Decision
- HAFN Strong Buy
- GH Strong Buy
- Analyst Count
- HAFN 1
- GH 17
- Target Price
- HAFN $10.00
- GH $39.31
- AVG Volume (30 Days)
- HAFN 1.0M
- GH 2.3M
- Earning Date
- HAFN 01-01-0001
- GH 11-04-2024
- Dividend Yield
- HAFN 23.17%
- GH N/A
- EPS Growth
- HAFN N/A
- GH N/A
- EPS
- HAFN 1.56
- GH N/A
- Revenue
- HAFN $2,970,261,000.00
- GH $643,810,000.00
- Revenue This Year
- HAFN N/A
- GH $27.01
- Revenue Next Year
- HAFN N/A
- GH $18.30
- P/E Ratio
- HAFN $4.53
- GH N/A
- Revenue Growth
- HAFN 18.39
- GH 26.20
- 52 Week Low
- HAFN $6.96
- GH $15.81
- 52 Week High
- HAFN $8.99
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- GH 31.05
- Support Level
- HAFN N/A
- GH $25.51
- Resistance Level
- HAFN N/A
- GH $26.85
- Average True Range (ATR)
- HAFN 0.00
- GH 1.07
- MACD
- HAFN 0.00
- GH -0.36
- Stochastic Oscillator
- HAFN 0.00
- GH 4.32
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is a shipping company. It provides transportation of oil and oil products and also owns and operates oil product tankers. It offers fleet and bunkers services. The group operates through four segments namely LR2 Product Tankers, LR1 Product Tankers, MR and Chemical-MR segment, and Handy and Chemical-Handy segment. It generates maximum revenue from the LR1 Product Tankers segment.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.